Join us for an informative report back from the San Antonio Breast Cancer Symposium (SABCS 2025) with Dr. Eleonora Teplinsky, gynecologic and breast medical oncologist at Valley Health. This session will break down the latest research and key takeaways in early-stage breast cancer, translating complex science into clear, practical insights.
Whether you’re a patient, survivor, caregiver, or advocate, this is an opportunity to hear trusted, up-to-date information directly from a highly respected oncologist and gain clarity on what recent advances may mean for care today and in the future.
TAKEAWAYS:
Oral SERDs will likely change the treatment paradigm for early stage HR+/HER2- breast cancer. Questions remain including use of CDK 4/6 inhibitors, sequencing of treatment, cost, ? Future role in HER2+
Trastuzumab deruxtecan (T-DXd) will become increasingly utilized in early stage HER2-positive breast cancer with evidence supporting its role in both neoadjuvant and adjuvant settings
Role of carboplatin continues to evolve in TNBC and remains nuanced
Personalized breast cancer risk screening and screening strategies are advancing, signaling a shift toward risk-adapted, personalized approaches
Survivorship and menopause research is critical and beginning to focus on topics such as MHT, GLP-1 use and others